At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 53 enrolled
Drug / intervention
Sublingual Sufentanildrug
Likely dose
Sublingual Sufentanil 30 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intraoperative Sublingual Sufentanil for Acute Pain in the Ambulatory Surgery Center
In Brief
A Phase 4 clinical trial evaluating Sublingual Sufentanil for Pain and 2 related conditions. Completed, enrolled 53 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if a single dose of sublingual sufentanil given 15-30 minutes prior to wake up is efficacious at reducing recovery room time.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Pain, Acute, Anesthesia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartOct 2020
Primary CompletionFeb 2021
TodayJul 2026
First PostedMay 13, 2020
Enrollment StartOct 14, 2020
Primary CompletionFeb 4, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.1 years ago
Interventions
Sublingual Sufentanildrug
15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.